Celyad Oncology SA (EBR:CYAD)
Belgium
· Delayed Price · Currency is EUR 0.4810
+0.0010 (0.21%)
Apr 25, 2025, 5:35 PM CET
Celyad Oncology Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 0.19 | 0.1 | - | - | 0.01 | Upgrade
|
| Revenue Growth (YoY) | 82.35% | - | - | - | -16.67% | Upgrade
|
| Cost of Revenue | 0.01 | 0.07 | - | - | - | Upgrade
|
| Gross Profit | 0.17 | 0.03 | - | - | 0.01 | Upgrade
|
| Selling, General & Admin | 3.2 | 6.25 | 10.56 | 10 | 9.39 | Upgrade
|
| Research & Development | 3.24 | 4.38 | 18.91 | 20.69 | 21.44 | Upgrade
|
| Other Operating Expenses | -0.4 | -1.09 | -4.03 | -3.44 | -4.59 | Upgrade
|
| Operating Expenses | 6.03 | 9.55 | 25.45 | 27.24 | 26.25 | Upgrade
|
| Operating Income | -5.86 | -9.51 | -25.45 | -27.24 | -26.24 | Upgrade
|
| Interest Expense | -0.12 | -0.08 | -0.2 | -0.26 | -0.3 | Upgrade
|
| Interest & Investment Income | 0.15 | 0.03 | 0.01 | 0.03 | 0.05 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -0 | 0.17 | 0.01 | -0.14 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | -0 | 0.11 | 0.17 | Upgrade
|
| EBT Excluding Unusual Items | -5.82 | -9.57 | -25.46 | -27.35 | -26.46 | Upgrade
|
| Impairment of Goodwill | - | - | -0.64 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 1.06 | 5 | -0 | 0.03 | Upgrade
|
| Asset Writedown | - | - | -34.44 | - | - | Upgrade
|
| Other Unusual Items | - | - | 14.68 | 0.85 | 9.23 | Upgrade
|
| Pretax Income | -5.82 | -8.51 | -40.87 | -26.5 | -17.2 | Upgrade
|
| Income Tax Expense | - | -0.06 | 0.07 | 0.01 | - | Upgrade
|
| Net Income | -5.82 | -8.45 | -40.94 | -26.51 | -17.2 | Upgrade
|
| Net Income to Common | -5.82 | -8.45 | -40.94 | -26.51 | -17.2 | Upgrade
|
| Shares Outstanding (Basic) | 42 | 26 | 23 | 16 | 14 | Upgrade
|
| Shares Outstanding (Diluted) | 42 | 26 | 23 | 16 | 14 | Upgrade
|
| Shares Change (YoY) | 61.73% | 13.84% | 44.80% | 11.92% | 11.33% | Upgrade
|
| EPS (Basic) | -0.14 | -0.33 | -1.81 | -1.70 | -1.23 | Upgrade
|
| EPS (Diluted) | -0.14 | -0.33 | -1.81 | -1.70 | -1.23 | Upgrade
|
| Free Cash Flow | -5.68 | -16.1 | -28.13 | -26.97 | -27.82 | Upgrade
|
| Free Cash Flow Per Share | -0.14 | -0.63 | -1.25 | -1.73 | -2.00 | Upgrade
|
| Gross Margin | 93.55% | 32.35% | - | - | 100.00% | Upgrade
|
| Operating Margin | -3149.46% | -9325.49% | - | - | -524800.00% | Upgrade
|
| Profit Margin | -3131.18% | -8282.35% | - | - | -344080.00% | Upgrade
|
| Free Cash Flow Margin | -3053.76% | -15785.29% | - | - | -556300.00% | Upgrade
|
| EBITDA | -5.35 | -9 | -24.74 | -26.68 | -24.41 | Upgrade
|
| D&A For EBITDA | 0.51 | 0.51 | 0.71 | 0.56 | 1.83 | Upgrade
|
| EBIT | -5.86 | -9.51 | -25.45 | -27.24 | -26.24 | Upgrade
|
Updated Sep 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.